Laboratory Risk Indicator for Necrotizing Fasciitis of the Oro-Cervical Region (LRINEC-OC): A Possible Diagnostic Tool for Emergencies of the Oro-Cervical Region.

Laboratory Risk Indicator for Necrotizing Fasciitis of the Oro-Cervical Region (LRINEC-OC): A Possible Diagnostic Tool for Emergencies of the Oro-Cervical Region.

necrotizing fasciitis (OCNF) Oro-cervical treatment requires early surgical debridement and wound opening, and therefore, early diagnosis is crucial. Laboratory Risk Indicator for Necrotizing fasciitis (LRINEC) scores based on data from blood tests recently proposed as an additional diagnostic tool. However, in some cases, be difficult to diagnose OCNF. We conducted a pooled analysis of patients … Czytaj dalej

A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine

A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine

Biomarkers to guide treatment decisions antibiotics has been proposed as an effective way to increase the use of more appropriate antibiotics. As a biomarker, procalcitonin (PCT) has been found to have good specificity to distinguish bacterial from non-bacterial inflammation. Decisions regarding the use of antibiotics in complex individual patient and should be based on the … Czytaj dalej

Planning Risk-Based Statistical Quality Control Strategies: Graphical Tools to Support the New Clinical and Laboratory Standards Institute C24-Ed4 Guidance

Planning Risk-Based Statistical Quality Control Strategies: Graphical Tools to Support the New Clinical and Laboratory Standards Institute C24-Ed4 Guidance

Background: Clinical and Laboratory Standards Institute (CLSI) 's new guidelines for statistical quality control (SQC; C24-ED4) (CLSI C24-ED4, 2016; Parvin CA, 2017) recommended the implementation of a risk-based SQC strategy. Important changes from the previous edition include the alignment of the principles and concepts of the model of the patient’s risk common in CLSI EP23A … Czytaj dalej

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand

Objective: CML genetic characteristic known as the appearance of t (9; 22) (q34.1; q11.2) (BCR-ABL1), which is present in more than 95% of cases. Here, we demonstrate a practical laboratory tool for monitoring the BCR-ABL1 transcripts in patients with chronic myeloid leukemia who underwent TK inhibitor therapy. Methods: Real-time quantitative PCR and direct sequencing to … Czytaj dalej